Screener
ANI Pharmaceuticals ANIP Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses and other | 16,575 | 16,970 |
| Income taxes payable | 3,532 | 2,239 |
| Current debt, net | 21,329 | 17,268 |
| Total Current Liabilities | 283,655 | 278,112 |
| Non-current Liabilities | ||
| Debt, net | 280,155 | 291,840 |
| Convertible notes, net | 309,009 | 307,927 |
| Contingent consideration | 8,546 | 9,610 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's total current liabilities?
- ANI Pharmaceuticals (ANIP) reported total current liabilities of $283.66M in Q2 2026.
- How has ANI Pharmaceuticals's total current liabilities changed year-over-year?
- ANI Pharmaceuticals's total current liabilities increased by 19.8% year-over-year, from $236.84M to $283.66M.
- What is the long-term trend for ANI Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's total current liabilities has grown at a 28.8% compound annual growth rate (CAGR), from $78.57M to $278.11M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about ANI Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude